Two new oral disease modifying therapies in relapsing remitting multiple sclerosis

被引：0
|
作者：
Lebrun, C. [1 ]
de Seze, J. [2 ]
机构：
[1] Hop Louis Pasteur, Serv Neurol, F-06002 Nice 1, France
[2] Hop Hautepierre, Serv Neurol, F-67000 Strasbourg, France
来源：
REVUE NEUROLOGIQUE | 2014年 / 170卷 / 12期
关键词：
PLACEBO-CONTROLLED PHASE-3; DOUBLE-BLIND; TERIFLUNOMIDE; TRIAL; BG-12;
D O I：
10.1016/j.neurol.2014.11.002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：721 / 722
页数：2
相关论文
共 50 条
  • [31] Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019)
    Goudarzi, Mohaddeseh H.
    Eadie, Mervyn J.
    Hollingworth, Samantha A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [32] Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Marita Zimmermann
    Elizabeth Brouwer
    Jeffrey A. Tice
    Matt Seidner
    Anne M. Loos
    Shanshan Liu
    Richard H. Chapman
    Varun Kumar
    Josh J. Carlson
    CNS Drugs, 2018, 32 : 1145 - 1157
  • [33] Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment
    Grand'Maison, Francois
    Yeung, Michael
    Morrow, Sarah A.
    Lee, Liesly
    Emond, Francois
    Ward, Brian J.
    Laneuville, Pierre
    Schecter, Robyn
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1419 - 1430
  • [34] EFFICACY AND SAFETY OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [35] Efficacy of Natalizumab after Insufficient Response to Other Disease Modifying Therapies for the Treatment of Relapsing Remitting Multiple Sclerosis
    Putzki, Norman
    NEUROLOGY, 2010, 74 (09) : A553 - A553
  • [36] Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis
    Liu, Zhuoyi
    Liao, Qiao
    Wen, Haicheng
    Zhang, Yihao
    AUTOIMMUNITY REVIEWS, 2021, 20 (06)
  • [37] Relapsing–Remitting Multiple Sclerosis: Patterns of Response to Disease-Modifying Therapies and Associated Factors: A National Survey
    Sá M.J.
    de Sá J.
    Sousa L.
    Neurology and Therapy, 2014, 3 (2) : 89 - 99
  • [38] Predictors of Response to First-Line Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Castillo-Trivino, Tamara
    Gajofatto, Alberto
    Bacchetti, Peter
    Waubant, Emmanuelle
    NEUROLOGY, 2010, 74 (09) : A155 - A155
  • [39] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [40] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
12345